Ring Therapeutics

Ring Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2017 by Flagship Pioneering.

The company focuses on advancing gene therapy through its proprietary AnellogyTM platform, which utilizes engineered anelloviruses from the human commensal virome to create programmable genetic medicines. This innovative approach aims to develop life-saving, redosable, and tissue-specific therapies that address the limitations of current gene therapy methods. The primary product of Ring Therapeutics is AnellovectorsTM, a novel gene therapy vector platform designed for various therapeutic applications, including genetic disorders, ophthalmology, oncology, and metabolic disorders. The company has also developed AnelloBricks®, a biomanufacturing platform that enhances the production of Anellovectors. Ring Therapeutics serves the healthcare and life sciences sectors, providing advanced viral vector technologies to researchers and developers in the gene therapy field. With over $253 million in funding, including a recent Series C round, the company is well-positioned to continue its growth and innovation in gene therapy.